Sign up to access historical data
Similar companies
| Company | Est. Transaction Value | |
|---|---|---|
 |
Gilead SciencesGILD |
$81,000 |
 |
AmgenAMGN |
$160,000 |
 |
BridgeBio PharmaBBIO |
$40,000 |
 |
TuHURA BiosciencesHURA |
$83,000 |
 |
GenprexGNPX |
$24,000 |
Trades by US Politicians
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Jefferson Shreve | May 12, 2025 | Sell | $15K - $50K |
FAQ - Congress Trading
Jefferson Shreve sold Alnylam Pharmaceuticals shares most recently on May 12, 2025.
Jefferson Shreve has sold the most ALNY stock in the last 2 years, with an estimated value of $33,000.
The net value of trades by US politicians for Alnylam Pharmaceuticals in the last 2 years is negative, amounting to -$33,000. This suggests that US politicians do not believe in the success of the company for various reasons.
Over the last 2 years, insider transactions for Alnylam Pharmaceuticals have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering politicians might have insights or reasons not immediately apparent to the public.
Monitoring US politicians' stock trades is valuable because they may have inside information about upcoming policies that could affect stock values, providing investors with valuable clues for making informed decisions.
